Introduction
In France, maintenance programmes for major opioid drug addiction were adopted later than in many other European countries or in the United States. For many years, withdrawal was the only form of management for drug-dependent individuals. Two products are now prescribed for opiate dependence: methadone and high dosage (HD) buprenorphine, under the trade name SubutexÒ. There are no speci c guidelines for choosing between the two drugs. Between 1973 and 1995, methadone was restricted to exper-imental settings, with a limited number of patients in only two centres in Paris. 1 From January 1995 the drug was authorized as a maintenance treatment, to be delivered only in specialized care centres as speci ed by law. There is regular follow-up of patients ; the daily dose is consumed at the centre in the presence of a physician and occasional toxicology testing is performed on urine samples. If patients do not consent to the terms of the "care contract", they may be excluded from the centre and deprived of their treatment. Once subjects have been stable for a certain time, outside physicians in contact with the care centre are authorized to continue the prescription. As regards buprenorphine, this drug was approved in a high dosage formulation by the French Drug Agency in 1996. 2 In order to improve access to this new maintenance treatment, market approval was associated with two speci c measures by the French Ministry of Health: providing for the drug to be available in pharmacies and from any physician, including a general practitioner (GP). 3 The prescription may in principle form part of a comprehensive care contract, with psychological and social management ("within protocol"). The drug is distributed under a moderate level of surveillance. Currently, about 65 000 opiate users have access to maintenance treatment, with 57 000 buprenorphine and 7000 methadone consumers. 4 At the request of the French health authorities, routine evaluation of these two maintenance programmes was put into effect. 5, 6 Whereas numerous studies had evaluated the methadone programme, there was a lack of data on high dosage buprenorphine. 7, 8 Some misuse was rst reported in the social and medical environment and later in research samples. [9] [10] [11] [12] Fatal overdose, intravenous drug use, multi-drug addiction, illicit drug acquisition and heroin or cocaine use were frequently described practices. 13 It is dif cult to con rm whether this behaviour was due to the nature of the drug or to its distribution practices in terms of prescription and delivery (duration of the prescription, whether delivered in specialized centres or in pharmacies) or to monitoring practices (urine sample control or no control).
The aims of the present study were: (1) to compare the socio-demographic pro les, and drug consumption practices of two groups of consumers attending care centres: the methadone group and the high dosage buprenorphine group; and (2) to focus on the high dosage buprenorphine subgroups, comparing "within protocol" subjects (with psychological and social management) and "outwith protocol" subjects (without special management), and comparing subjects under the care of a GP with those who attended a specialized centre.
Methodology
In France, observation and evaluation of drug abuse and dependence linked to drugs or to psychoactive medication is the responsibility of the Commission for Narcotics and Psychotropic Drugs, which is supervised by the French Drug Agency. Six Centres for Evaluation and Information on Pharmaco-Dependence (CEIP) were created in 1990 to assist the Commission in carrying out evaluation and collection of clinical data. Among the various studies developed by this regional network, an original observation programme was established in 1990: OPPIDUM (Observation of Illegal Drugs and Misused Psychotropic Medications). 14, 15 The CEIPs supervise the survey and select the programme co-ordination centres.
Oppidum is a 4-week-long study conducted annually which investigates drug dependent subjects entering specialized care centres. The 1998 survey studied different voluntary and regular care structures such as outpatient drug addiction centres, hospital units and emergency units. 15 The subjects were people attending the centre and presenting with drug dependence as de ned by DSM-IV criteria (Diagnostic and Statistical Manual IV, American Psychiatric Association). This could be dependence on licit or illicit drugs, including dependence on maintenance treatments such as methadone and HD buprenorphine. Patients presenting with an isolated dependence with tobacco or alcohol were excluded. The data were collected anonymously by means of a standardized questionnaire administered at the centre. The rst part concerned socio-demographic data (age, sex, level of education, economic situation) and other addiction behaviour information (tobacco, alcohol). The second part concerned the drugs consumed by the patient during the previous week. For each product the trade name and the galenic presentation were collected, as were the dosage and frequency of consumption, and administration and acquisition methods. 15, 16 For the univariate analysis, the usual tests were used to compare the different groups (v 2 and Fisher's exact tests for the qualitative variables, comparisons of means for the quantitative variables). Differences were considered signi cant when the p value was , 0.05. In addition, adjusted odds ratios were calculated from the estimate of beta coef cient in the forward-stepwise logistic regression analysis, which was performed to assess the independent association of buprenorphine consumers with predictive variables, compared to the methadone group. The 10 variables initially entered in the model were: sex, education level, economic situation, whether living with a partner, professional activity, concomitant cocaine consumption, concomitant heroin consumption, concomitant cannabis consumption, only treatment substitution intake and intravenous use.
Results
During October 1998, 46 centres participated in this study, including 1462 subjects. Refusals were exceptional ( , 1%). Seventy per cent of all subjects were undergoing at least one maintenance treatment. Methadone consumption was reported by 424 patients and high dosage buprenorphine by 616. Subjects using other products (422) were not analysed in this study. (Table 1) · Socio-demographic characteristics The methadone group was older and contained a higher proportion of women. The education level was similar for the two groups. Patients in the methadone group reported a generally higher economic situation but with more unemployment.
Comparison of the two groups of consumers: methadone and high dosage buprenorphine

· Other drug use
Concerning tobacco and alcohol, no difference was found between the two groups. Benzodiazepine consumption was noted in a quarter of patients in each category, three-quarters of whom used it daily. The buprenorphine group used mainly unitrazepam, acquired generally by illicit means (dealing or falsi ed prescriptions).
On the other hand, signi cant differences were observed concerning illicit consumption. Cocaine was used by 16% of methadone subjects versus 8% of buprenorphine users, heroin by 8% of methadone subjects versus 12% of buprenorphine users.
· Maintenance treatment consumption modalities
Approximately 100 of the 616 buprenorphine patients reported intravenous use and 23 used a nasal route. These two routes of administration were never reported by the methadone patients. All methadone subjects with daily consumption acquired their dose by medical prescription. However, a number of buprenorphine subjects (n 5 49) with irregular consumption acquired the substance through deals. (Table 2) In the high dosage buprenorphine group (616), 559 subjects were identi ed as "within protocol" (consuming the drug in a strict care protocol, with a correct follow-up) and 57 "outwith protocol" (consuming the drug without any supervision). Many differences were noted between the two groups. The "outwith protocol" subjects were younger, in a more precarious economic situation and displayed more misuse behaviour. They reported more illicit drug use (heroin: 33% vs. 10%, cocaine: 19% vs. 7%) and more psychotropic drug use, such as benzodiazepines (44% vs. 20%). They used an intravenous route more frequently. The consumption pro le of the "within protocol" subjects resembled that of methadone subjects. Of the "within protocol" buprenorphine consumers, 328 received their treatment at a centre and 207 from a general practitioner. The subjects attending a centre presented a pattern of consumption behaviour similar to that of the methadone subjects. Furthermore, the subjects managed by a GP presented consumption behaviour similar to the buprenorphine "outwith protocol" subjects. The high dosage buprenorphine users (p , 0.05), compared with the methadone group, were younger, male, did not live as a couple; did not consume cocaine, tended to use an intravenous route and did not restrict their intake to the substitution treatment. : Signi cance between "within protocol" group and "outwith protocol" group; p 2 : signi cance between "centre follow-up" group and "GP's follow-up" group; * 4 2 and Fisher's exact tests for the qualitative variables, comparisons of means for the quantitative variables. *NS: non-signi cant; GP: general practitioner.
Comparison between subgroups of buprenorphine
Discussion
In France, the evaluation of maintenance programmes remains incomplete. Various hypotheses may be put forward to explain this. First, the illegal nature of illicit drug use makes investigation of these populations dif cult. The questionnaire answers may be in uenced by the social acceptability of the illicit product; therefore, the data validity should always be considered with care. 17, 18 A second issue is that the majority of available data comes from institutions such as care or social centres and re ects only part of the global situation. Some opiate users or maintenance treatment users will probably never be included in these care structures and therefore fall outside any formal investigation. In this particular study, the aim was to compare the methadone and the buprenorphine groups attending care centres. Thus, the results cannot be generalised to the maintenance treatment population as a whole. 19 Notably, data from GPs are missing. These data would certainly provide pertinent information concerning the high dosage buprenorphine consumers. The information from this study is not representative of the global management system of maintenance programmes in France as no data were collected from less socially integrated subjects who never attend care centres or use only "lowthreshold" services. Despite the complexity of this eld, if all the limitations are recognized and taken into consideration when the results are interpreted, it might be possible to crosscheck with data from other information sources in order to identify trends and formulate hypotheses. Methodologies must be homogenized in order to compare French results with European or American data, as recommended by the French health authorities. 20 It was dif cult to verify the inclusion criteria because of the plurality and diversity of the investigators and survey centres and because of the imprecision or complexity of the concepts used (some criteria were subjective). To minimize this bias, the investigators were reminded regularly of these strict criteria.
The Oppidum programme does, however, have some clear advantages: an annual national survey, regular and systematic information collection using the same questionnaires in each centre, prospective data collecting and feasible and practicable investigation methods. Each year, the number of centres and patients taking part increases, demonstrating the motivation of personnel and the feasibility of the project. This survey is now functioning routinely and should provide a relevant tool within the French addiction survey system. This particular sample of maintenance treatment consumers did not differ socio-demographically from other French and Anglo-Saxon published data. The mean age was around 27 or 30 years, the proportion of women was around a quarter, two-thirds were unmarried and 25% had children. 3, 4, 7, 13 The high level of multi-drug use was in accordance with other studies. Several of cial reports, such as those of the French High Public Health Commission 21 or French Drug and Addiction Observatory, 4 have provided data showing the high frequency of multi-drug addictions in opiate users or in maintenance treatment consumers. Alcohol and tobacco use are common in these patients and are frequently reported in addition to other drugs (licit or illicit, intravenous or not). In our study, data were collected only on drugs consumed during the previous week, to make it easier for patients to remember. It is therefore probable that the results underestimated the real situation.
Pharmacological interactions between any of the consumed products can be dangerous. Some scienti c publications have reported deaths related to the association of benzodiazepines and high dosage buprenorphine. 11, 12 This class of drugs, mainly unitrazepam, obtained easily in France by medical prescription, was consumed by 25% of the subjects in this study. Several authors have reported a high likelihood of unitrazepam abuse. [22] [23] [24] Concerning heroin, the net decrease in consumption over time is encouraging; this is often considered to be the major criterion of success in maintenance programmes. 25, 26 In the present study the decrease was more noticeable in the methadone subjects and was con rmed by some other studies, 27 but remains uncon rmed in others. 28 In contrast, an increase in cocaine consumption has been shown in methadone programmes in France as well as in the United States. [29] [30] [31] Regrettably, some subjects appear to have started using cocaine only when they began maintenance treatment. 32 The subjective effect of heroin is reduced when it is combined with methadone, while cocaine retains its pharmacological effects. 32 One of the objectives of the distribution of high dosage buprenorphine was to decrease this use. Our results were encouraging, showing lower cocaine consumption in the buprenorphine group (8%) compared with the methadone group (16%), but continued use of cocaine is a well-known phenomenon in substitution treatment failure. Intravenous use remains an issue of serious concern. Many researchers have tried to explain this persistent phenomenon in subjects undergoing maintenance programmes. It appears that inadequate dosage adaptation induces a withdrawal syndrome leading the patient to nd alternative sensations of wellbeing. None the less, even when assays are adapted, patients continue with their injection behaviour. Buprenorphine, extracted and soluble in water, can be injected easily; consequently, these practices are usually described in buprenorphine subjects, as this study con rms. The care centre group was less prone to these practices than the group managed by GPs.
Buprenorphine was procured illegally in 8% of cases ("black market" dealing, theft, falsi ed prescriptions), a behaviour noted in other French studies. 33, 34 In France, a patient can visit several GPs and procure substantial quantities of the drug. This is known as "nomadism". The French authorities are working to develop tighter controls. 20 In conclusion, does the success of maintenance programmes really depend on the nature of the maintenance drug, or on delivery modality and management? No specialized quali cations or experience are required for GPs to prescribe buprenorphine, unlike methadone prescription, which requires specialized training. 35 The patients are, however, often undisciplined and may be dif cult to manage; adaptation in dosage is dif cult to achieve 36 and follow-up is very irregular. In contrast, patients attending specialized centres are managed by specialized practitioners with more experience. A report by McLellan and colleagues demonstrated a wide variation in retention rate in maintenance programmes depending on the nature of the follow-up: 80% for subjects who underwent urine controls and medico-social management and 20% for subjects with no special management. 37 Whereas some health and medical authorities are convinced of the potential of buprenorphine treatment to help patients modify their drug consumption, others remain sceptical of the bene ts of the French system. European governments and investigators await more objective data. 8 The objectives of maintenance treatment policies have, of course, altered over time. Initially the aim was to obtain complete abstinence and a life without drug addiction, but it has become progressively more important to help opiate users to regain at least some stability in their daily lives. At a recent consensus conference, maintenance was de ned as a addiction regulation tool and not as a method of weaning (Consensus conference: withdrawal modalities for opiate users 1998). The importance of maintenance treatment is now recognized, but the prescription and the delivery modalities need to be reviewed. 
